Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: Potential targets for cancer control

Toxicology and Applied Pharmacology

Volumn 280, Issue 2, 2014, Pages 296-304

  Pandey, Manuraj ^a   Sahay, Satya ^a   Tiwari, Prakash ^a   Upadhyay, Daya S ^b   Sultana, Sarwat ^c   Gupta, Krishna P ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

EZH2; G9a histone methylation; Inositol hexaphosphate; Lung cancer; SUV39H1; Urethane

Indexed keywords

G9A PROTEIN; HISTONE; HISTONE H3; HISTONE H4; MICRORNA; MICRORNA 138; PHYTIC ACID; PROTEIN; PROTEIN MLH1; PROTEIN P16; SUV39H1 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; URETHAN; EZH2 PROTEIN, MOUSE; G9A PROTEIN, MOUSE; HISTONE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE; KDM6B PROTEIN, MOUSE; METHYLTRANSFERASE; MIRN138 MICRORNA, MOUSE; POLYCOMB REPRESSIVE COMPLEX 2; REPRESSOR PROTEIN; SUV39H1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE TARGETING; HISTONE MODIFICATION; LUNG CARCINOGENESIS; LUNG TUMOR; MICROCHIP ANALYSIS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; GENETICS; METABOLISM; METHYLATION; PHYSIOLOGY; TOXICITY;

ANIMALS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LUNG NEOPLASMS; METHYLATION; METHYLTRANSFERASES; MICE; MICE, INBRED BALB C; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; URETHANE;

EID: 84907818044     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.08.015     Document Type: Article

References (43)

1. Berghe W.V. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol. Res. 2012, 65:565-576.
2. Broeck A.V.D., Brambilla E., Moro-Sibilot D., Lantuejoul S., Brambilla C., Eymin B., Khochbin S., Gazzeri S. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 2008, 14:7237-7245.
3. Chang C.J., Hung M.C. The role of EZH2 in tumor progression. Br. J. Cancer 2012, 106:243-247.
4. Chen M.W., Hua K.T., Kao H.J., Chi C.C., Wei L.H., Johansson G., Shiah S.G., Chen P.S., Jeng Y.M., Cheng T.Y., Lai T.C., Chang J.S., Jan Y.H., Chien M.H., Yang C.J., Huang M.S., Hsiao M., Kuo M.L. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010, 70:7830-7840.
5. Chi P., Allis C.D., Wang G.G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
6. Crea F., Fornaro L., Bocci G., Sun L., Farrar W.L., Falcone A., Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012, 31:753-761.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
8. Fan D.N., Tsang F.H., Tam A.H., Au S.L., Wong C.C., Wei L., Lee J.M., He X., Ng I.O., Wong C. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 2013, 57:637-647.
9. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Pérez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
10. Fussbroich B., Wagener N., Goeppinger S.M., Benner A., Falth M., ltmann H.S., Holzer A., Hoppe-Seyler K., Hoppe-Seyler F. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 2011, 6:e21651.
11. Gerhauser C. Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges. Top. Curr. Chem. 2013, 329:73-132.
12. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13:343-357.
13. Gupta K.P., Singh J., Bharathi R. Suppression of DMBA induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr. Cancer 2003, 46:66-72.
14. He Y., Korboukh I., Jin J., Huang J. Targeting protein lysine methylation and demethylation in cancers. Acta Biochim. Biophys. Sin. 2012, 44:70-79.
15. Hursting S.D., Slaga T.J., Fischer S.M., DiGiovanni J., Phang J.M. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. J. Natl. Cancer Inst. 1999, 91:215-225.
16. Incoronato M., Urso L., Portela A., Laukkanen M.O., Soini Y., Quintavalle C., Keller S., Esteller M., Condorell G. Epigenetic regulation of miR-212 expression in lung cancer. PLoS ONE 2011, 6:e27722.
17. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Malone W.A., Boone C.W., Kopelovich L., Hawk E.T., Lieberman R., Lawrence J.A., Ali I., Viner J.L., Sigman C.C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 2000, 130:467S-471S.
18. Kondo Y., Shen L.L., Issa J.P.J. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 2003, 23:206-215.
19. Kondo Y., Shen L., Suzuki S., Kurokawa T., Masuko K., Tanaka Y., Kato H., Mizuno Y., Yokoe M., Sugauchi F., Hirashima N., Orito E., Osada H., Ueda R., Guo Y., Chen X., Issa J.P.J., Sekido Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 2007, 37:974-983.
20. Kondo Y., Shen L., Ahmed S., Boumber Y.S., Sekido Y., Haddad B.R., Issa J.P.J. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 2008, 3:e2037.
21. Lakshmikuttyamma A., Scott S.A., DeCoteau J.F., Geyer C.R. Re-expression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010, 28:576-588.
22. Liu S., Wu L.C., Pang J., Santhanam R., Schwind S., Wu Y.Z., Hickey C., Yu J., Becker H., Maharry K., Radmacher M.D., Li C., Whitman S.P., Mishra A., Stauffer N., Eiring A.M., Briesewitz R., Baiocchi R.A., Chan K.K., Paschka P., Caligiuri M.A., Byrd J.C., Croce C.M., Bloomfield C.D., Perrotti D., Garzon R., Marcucci G. Sp1/NFκB/HDAC/miR-29b regulatory network in kit-driven myeloid leukemia. Cancer Cell 2010, 17:333-347.
23. Liu X., Wang C., Chen Z., Jin Y., Wang Y., Kolokythas A., Dai Y., Zhou X. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J. 2011, 440:23-31.
24. Martinez-Garcia E., Licht J.D. Deregulation of H3K27 methylation in cancer. Nat. Genet. 2010, 42:100-101.
25. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., LaFrance L.V., Mellinger M., Duquenne C., Tian X., Kruger R.G., McHugh C.F., Brandt M., Miller W.H., Dhanak D., Verma S.K., Tummino P.J., Creasy C.L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
26. Mori M., Rao S.K., Popper H.H., Cagle P.T., Fraire A.E. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod. Pathol. 2001, 14:72-84.
27. Nikitin A.Y., Alcaraz A., Anver M.R., Bronson R.T., Cardiff R.D., Dixon D., Fraire A.E., Gabrielson E.W., Gunning W.T., Haines D.C., Kaufman M.H., Linnoila R.I., Maronpot R.R., Rabson A.S., Reddick R.L., Rehm S., Rozengurt N., Schuller H.M., Shmidt E.N., Travis W.D., Ward J.M., Jacks T. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 2004, 64:2307-2316.
28. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemo resistance by the histone methyl transferase EZH2. Clin. Cancer Res. 2008, 14:6790-6796.
29. Pandey M., Gupta K.P. Epigenetics, an early event in the modulation of gene expression by inositol hexaphosphate in ethylnitrosourea exposed mouse lungs. Nutr. Cancer 2011, 63:89-99.
30. Pandey M., Gupta K.P. Involvement of STAT3, NF-κB and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse. Environ. Toxicol. Pharmacol. 2012, 34:502-511.
31. Pandey M., Sultana S., Gupta K.P. Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors. Exp. Mol. Pathol. 2014, 96:61-70.
32. Risch A., Plass C. Lung cancer epigenetics and genetics. Int. J. Cancer 2008, 123:1-7.
33. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
34. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174:1619-1628.
35. Shinkai Y., Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev. 2011, 25:781-788.
36. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hyper trimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20980-20985.
37. Takeshima H., Ikegami D., Wakabayashi M., Niwa T., Kim Y.J., Ushijima T. Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells. Carcinogenesis 2012, 33:2384-2390.
38. Tryndyak V.P., Kovalchuk O., Pogribny I.P. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol. Ther. 2006, 5:65-70.
39. Witcher M., Emerson B.M. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol. Cell 2009, 34:271-284.
40. Wongtawan T., Taylor J.E., Lawson K.A., Wilmut I., Pennings S. Histone H4K20me3 and HP1α are late heterochromatin markers in development, but present in undifferentiated embryonic stem cells. J. Cell Sci. 2011, 124:1878-1890.
41. Yokochia T., Poducha K., Rybaa T., Lua J., Hiratania I., Tachibanab M., Shinkaib Y., Gilbert D.M. G9a selectively represses a class of late-replicating genes at the nuclear periphery. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19363-19368.
42. Yost J.M., Korboukh I., Liu F., Gao C., Jin J. Targets in epigenetics: inhibiting the methyl writers of the histone code. Curr. Chem. Genomics 2011, 5:72-84.
43. Zhang H., Zhang H., Zhao M., Lv Z., Zhang X., Qin X., Wang H., Wang S., Su J., Lv X., Liu H., Du W., Zhou W., Chen X., Fei K. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell. Physiol. Biochem. 2013, 31:56-65.